VY 1706
Alternative Names: tau silencing gene therapy program; VY-1706Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Voyager Therapeutics
- Class Antidementias; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference; Tau protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 20 Nov 2024 Preclinical trials in Alzheimer's disease in USA (IV)
- 20 Nov 2024 Voyager Therapeutics plans to file an IND application to the US FDA for Alzheimer's disease in 2026
- 20 Nov 2024 Voyager Therapeutics plans to file an Clinical Trial Application (CTA) to the Canadian regulatory for Alzheimer's disease in 2026